Beuth J, Stoffel B, Ko H L, Jeljaszewicz J, Pulverer G
Institute of Medical Microbiology and Hygiene, University of Cologne, Germany.
Arzneimittelforschung. 1995 Nov;45(11):1240-2.
Commercially available mistletoe extract standardized for the galactoside-specific lectin (ML-1; Eurixor) and a chromatographically ML-1-depleted preparation (same charge no. and composition of remaining components) were tested for their immunomodulating potency. In BALB/c-mice, regular subcutaneous administration of the optimal immunomodulating dosage (1 ng ML-1/kg body weight) could be shown to induce no influence on spleen weight, a non-significant increase of thymus weight, a significant increase of thymocyte, peritoneal macrophage, peripheral blood leukocyte, lymphocyte and monocyte and monocyte counts, and a significant decrease of peripheral blood granulocyte counts. Administration of analogue volumes (concentrations) of ML-1-depleted extract, however, did not induce any immunopotentiation. Accordingly, it may be assumed, that the galactoside-specific lectin (ML-1) represents the main immunomodulating component in commercially available mistletoe extracts.
对市售的标准化半乳糖苷特异性凝集素（ML-1；Eurixor）槲寄生提取物和一种经色谱法去除ML-1的制剂（相同电荷数和其余成分组成）进行了免疫调节效力测试。在BALB/c小鼠中，定期皮下注射最佳免疫调节剂量（1 ng ML-1/千克体重）显示对脾脏重量无影响，胸腺重量有不显著增加，胸腺细胞、腹腔巨噬细胞、外周血白细胞、淋巴细胞和单核细胞计数显著增加，外周血粒细胞计数显著减少。然而，注射等量体积（浓度）的去除ML-1的提取物并未诱导任何免疫增强作用。因此，可以假定半乳糖苷特异性凝集素（ML-1）是市售槲寄生提取物中的主要免疫调节成分。
